Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients
Go back to Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 212.50 -8.33 (3.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $220.83 | 52 Week High | $333.65 | |||
| Open | $215.45 | 52 Week Low | $223.02 | |||
| Day High | $217.28 | P/E | 27.21 | |||
| Day Low | $210.54 | EPS | $7.81 | |||
| Volume | 617,406 | |||||
